Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | DRD2 | P14416 | 4/20 | 0.58 |
| ▸ | HTR2A | P28223 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.52 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.51 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30449208 | 1.00 | ALDH1A1 (0.60) | ALDH1A1MAPTDRD2HTR2AKDM4E | |
| SCHEMBL3291175 | 0.94 | ALDH1A1 (0.55) | ALDH1A1MAPTDRD2HTR2AKDM4E | |
| SCHEMBL565864 | 0.85 | KDM4E (0.61) | ALDH1A1MAPTDRD2HTR2AKDM4E | |
| SCHEMBL3287137 | 0.85 | KDM4E (0.61) | ALDH1A1MAPTDRD2HTR2AKDM4E | |
| SCHEMBL30748716 | 0.83 | KDM4E (0.59) | ALDH1A1MAPTDRD2HTR2AKDM4E | |
| SCHEMBL6822065 | 0.83 | KDM4E (0.59) | ALDH1A1MAPTDRD2HTR2AKDM4E | |
| SCHEMBL3290416 | 0.83 | KDM4E (0.59) | ALDH1A1MAPTDRD2HTR2AKDM4E | |
| SCHEMBL3291180 | 0.83 | KDM4E (0.67) | ALDH1A1MAPTDRD2HTR2AKDM4E | |
| SCHEMBL27939424 | 0.82 | KDM4E (0.58) | ALDH1A1MAPTDRD2HTR2AKDM4E | |
| SCHEMBL2750963 | 0.82 | KDM4E (0.58) | ALDH1A1MAPTDRD2HTR2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3820860-B1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 | LIEBER INST INC (US) | 2025-10-15 | — | — | EP | disclosed |
| US-11993581-B2 | Pyridazine compounds for inhibiting Nav1.8 | LIEBER INSTITUE, INC (US) | 2024-05-28 | — | — | US | disclosed |
| CN-112689629-B | For inhibiting Nav1.8 Pyridazine Compounds | 利伯研究所公司 | 2024-04-23 | — | — | CN | disclosed |
| EP-3820860-A1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 | Lieber Institute, Inc. (US) | 2021-05-19 | — | — | EP | disclosed |
| US-20210139456-A1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 | LIEBER INSTITUTE, INC | 2021-05-13 | — | — | US | disclosed |
| US-20210139456-A1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 | LIEBER INSTITUTE, INC | 2021-05-13 | — | — | US | disclosed |
| CN-112689629-A | For inhibiting Nav1.8 pyridazine Compounds | 利伯研究所公司 | 2021-04-20 | — | — | CN | disclosed |
| EP-2589592-B1 | NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF | FUJIFILM CORP (JP) | 2018-08-22 | — | — | EP | disclosed |
| US-20180201616-A1 | 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | GRUENENTHAL GMBH (DE) | 2018-07-19 | — | — | US | disclosed |
| US-20170197970-A1 | 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | GRUENENTHAL GMBH (DE) | 2017-07-13 | — | — | US | disclosed |
| US-8809371-B2 | — | — | 2014-08-19 | — | — | US | disclosed |
| US-8809371-B2 | — | — | 2014-08-19 | — | — | US | disclosed |
| US-8772320-B2 | — | — | 2014-07-08 | — | — | US | disclosed |
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2013-05-09 | — | — | US | disclosed |
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2013-05-09 | — | — | US | disclosed |
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2013-05-09 | — | — | US | disclosed |
| EP-2589592-A1 | NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF | FUJIFILM Corporation (JP) | 2013-05-08 | — | — | EP | disclosed |
| EP-2589592-A1 | NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF | FUJIFILM Corporation (JP) | 2013-05-08 | — | — | EP | disclosed |
| WO-2012002577-A1 | NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF | 富士フイルム株式会社 (JP) | 2012-01-05 | — | — | WO | disclosed |
| WO-2004043947-A1 | NOVEL PYRIDINE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LES LABORATOIRES SERVIER (FR) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139456-A1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 | SCN8A, SCN5A, SCN2A | ALDH1A1 3396/4885MAPT 1531/4885DRD2 2308/4885 |
| US-20170197970-A1 | 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | OPRK1, OPRD1, OPRL1 | ALDH1A1 337/4885MAPT 3629/4885DRD2 426/4885 |
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | SYK, CD38, BTK | ALDH1A1 1638/4885MAPT 4186/4885DRD2 1994/4885 |
| US-20180201616-A1 | 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | OPRK1, OPRD1, OPRL1 | ALDH1A1 337/4885MAPT 3629/4885DRD2 426/4885 |
| US-11993581-B2 | Pyridazine compounds for inhibiting Nav1.8 | SCN8A, SCN5A, SCN2A | ALDH1A1 3396/4885MAPT 1531/4885DRD2 2308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.